• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.


— February 23, 2017

Valneva Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017

Read more

— Stock information

@valnevase




















-
— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Read more
— Financial Calendar

February 23, 2017
Preliminary 2016 Results (Revenues, Cash)

March 23, 2017
2016 Financial Statements

See all dates



KOL event in N.Y. on Lyme disease (webcast)

Image_KOL-event.jpg



JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs



Credit Suisse 2017 Global Healthcare Conference
London, UK
February 28, 2017

World Vaccine Congress
Washington, US
April 10-12, 2017

10th Kempen Life Sciences Conference
Amsterdam, NL
April 18-19, 2017

Please update your browser...